Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). (Abstract 8047)
Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. (Abstract 8103)
A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. (Abstract 8030^)
Updated phase 1 results for TSR-011 from Tesaro
Results for RXDX-101 recently licensed from Nerviano in Italy by Ignyta.